Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects
Crossref DOI link: https://doi.org/10.1007/s00228-016-2108-z
Published Online: 2016-10-07
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hsyu, Poe-Hirr
Pignataro, Daniela Soriano
Matschke, Kyle
Funding for this research was provided by:
Pfizer Inc
License valid from 2016-10-07